GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SyntekaBio Inc (XKRX:226330) » Definitions » Capex-to-Operating-Cash-Flow

SyntekaBio (XKRX:226330) Capex-to-Operating-Cash-Flow

: 0.00 (As of Dec. 2023)
View and export this data going back to 2019. Start your Free Trial

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

SyntekaBio's Capital Expenditure for the three months ended in Dec. 2023 was ₩-3,391.57 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was ₩-1,866.56 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


SyntekaBio Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for SyntekaBio's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SyntekaBio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Premium Member Only Premium Member Only - - - - -

SyntekaBio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Health Information Services subindustry, SyntekaBio's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SyntekaBio Capex-to-Operating-Cash-Flow Distribution

For the Healthcare Providers & Services industry and Healthcare sector, SyntekaBio's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where SyntekaBio's Capex-to-Operating-Cash-Flow falls into.



SyntekaBio Capex-to-Operating-Cash-Flow Calculation

SyntekaBio's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-9429.603) / -8078.04
=N/A

SyntekaBio's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-3391.566) / -1866.559
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SyntekaBio  (XKRX:226330) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


SyntekaBio Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of SyntekaBio's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


SyntekaBio (XKRX:226330) Business Description

Traded in Other Exchanges
N/A
Address
187, Techno 2-ro, Yuseong-gu, Bi-dong, Yongsan-dong, Megan Techno World 2nd, Daejeon, KOR, 512
SyntekaBio Inc is a bioinformatics venture firm. It is engaged in gene-related research, technology development, and genetic analysis based on the genome big data platform and artificial intelligence deep learning drug development platform. The company manages and analyzes genome analysis and massive biodata and genome.

SyntekaBio (XKRX:226330) Headlines

No Headlines